Retirement of Jon Lamb

ADMIN
Thu, Sep 28 2023 12:08 pm





28 September 2023
Retirement of Jon Lamb

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Jon Lamb today retired from the board following his announcement at the ASM that he would be stepping down once a new independent director had been appointed. This is in conjunction with today’s appointment of Andrew Lane to the Board.
Chair David Flacks said: “On behalf of the Board I would like to extend my thanks to Jon for his outstanding service during his 11-year tenure. His deep industry knowledge and experience has enabled him to make a significant contribution to the growth and success of AFT, and it has been a privilege to work alongside him.”

Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.


For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals (ASX:AFP, NZX:AFT)
www.aftpharm.com
AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter, prescription, and hospital. AFT Pharmaceutical's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs.




Announcement PDF


Markets News

Sparks fly at Rakon meeting as Robinson eyes chair
Markets

Sparks fly at Rakon meeting as Robinson eyes chair

Robinson called for an extraordinary meeting to elect a “truly independent board”.

Finance

Stop raising bank capital ratios now, says competition report

Select committee recommends an immediate end to increasing capital ratios. 

Stop raising bank capital ratios now, says competition report
Primary Sector

'Pleasing for New Zealand': Market embraces Fonterra deal

Deal “starts one of the most exciting phrases in Fonterra’s history,” according to chair. 

'Pleasing for New Zealand': Market embraces Fonterra deal